ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1405

Evaluating the Cellular Composition of Anti-synthetase Syndrome and Dermatomyositis Skin Lesions Using Image Mass Cytometry

Jay Patel1, Adarsh Ravishankar1, Spandana Maddukuri2, Christina Bax3 and Victoria Werth4, 1University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, 2University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Montville, NJ, 3University of Pennsylvania, Department of Dermatology, Philadelphia, 4University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, PA

Meeting: ACR Convergence 2020

Keywords: autoimmune diseases, Dermatology, interferon

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 8, 2020

Title: T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Antisynthetase syndrome (AS) is a systemic autoimmune disorder characterized by the presence of anti-aminoacyl-tRNA synthetase antibodies, myositis, interstitial lung disease (ILD), mechanics hands, and raynaud’s phenomenon. Dermatomyositis (DM) is a similar autoimmune disorder with clinical features of muscle weakness, ILD, neoplasms, gottron’s papules, and photosensitive cutaneous manifestations. Currently most clinicians see AS as a subclassification under DM due to the many similarities. Recently some studies have emerged identifying differences in the type I interferon system between AS and DM muscle and finger eruptions. Type I interferons are amplified in autoimmune diseases such as DM, as demonstrated by proteins such as MxA expression.  To further characterize these differences, we investigated the cellular composition and inflammatory pathway profile using immunofluorescent staining (IF) and image mass cytometry (IMC).

Methods: We evaluated skin biopsies from back, arm, or leg of 7 DM patients, 3 AS patients, and 3 healthy control (HC). IF was performed on 3 biopsies from each group for IFNβ and MxA. Subsequently, IMC was implemented to further identify differences between DM and AS using metal conjugated antibodies. Biopsies were stained with a cocktail of markers and 1mm x 2mm regions were ablated using the Hyperion Imaging System. Cells were segmented using a nuclear app-based algorithm in Visiopharm. Per cell mean pixel intensity (MPI) analysis was performed using histoCAT. The Phenograph algorithm was used to cluster cells based on expression of cell type markers. The Kruskal Wallis test was used to identify immunofluorescence IFNβ and MxA differences between HC, DM, and AS groups corrected for multiple comparisons by controlling False Discovery Rate. The Mann Whitney test was used to identify differences in IMC cell populations and pathway expression between AS and DM skin lesions, including mDC IFNβ.

Results: IF of AS skin showed increased IFNβ and MxA compared to HC (p< 0.05, Fig 1) but there was no difference compared to DM IFNβ and MxA (p >0.05, Fig 1). IMC cell clusters in AS and DM were similarly distributed and we identified no differences in the cell populations (macrophages, T cells, and dendritic cells) of AS and DM (p >0.05, Fig 2). Despite no statistical differences in cells there is a trend for increased CD14+CD16+, mDCs, and pDCs in DM. Pathway expressions of pPPARγ, pSTING, IL31, IFNβ, MxA, pTBK1, IFNγ, and pERK also did not differ between AS and DM (p >0.05, Fig 3). The pIRF3, IL4, and IL17 pathways were increased in DM compared to AS skin lesion (p=0.04, 0.01, and 0.01, Fig 3). Both AS and DM mDCs produced IFNβ (Fig3), but there was no difference in mDC IFNβ between AS and DM (p >0.05, Fig 3).

Conclusion: A similar immune composition exists in AS and DM skin and there is a role for the type I interferon system in AS, however there may be differences in the extent of involvement due to decreased pIRF3,trends for decreased MxA, and dendritic cells. Additional differences in cytokines IL4 and IL17 exist with increased expression in DM. However, the two diseases overlap significantly supporting their current classification, but larger studies are still needed to clarify differences.

Immunofluorescence staining of IFNβ and MxA in HC, DM, and ASA skin a-c) HC skin has little IFNβ (green, a) compared to DM skin (b) and ASA skin (c). e-f) HC skin also has decreased MxA (red, d) compared to DM skin (e) and ASA skin (f) with DAPI in blue (a-f). Quantification of mean fluorescence intensity shows increased IFNβ in DM and ASA lesional skin compared to HC (g) and increased MxA expression in DM and ASA lesional skin compared to HC (h). Nuclei represented by DAPI (blue, a-f) * p < 0.05

Immune Cell quantification between HC, DM, and AS patients using Image Mass Cytometry PhenoGraph populations. a-b) Multiplexed image of lesional DM(a) and AS(b) skin revealing similar cells CD4 (red), CD8(green), DNA (blue), CD11C+ (white), BDCA1+ (cyan), and CD14+ (magenta) cells. c) The cell counts of CD14+, CD14+CD16+, MAC387+, CD4+, FOXP3+, Mast, CD56+, pSTING+CD14+CD16+, mDC, pDC, and CD8 were compared between DM and AS skin lesions. No significant differences were found between DM and AS for all cell populations.

Mean Pathway Expression in skin lesions of DM and ASA patients a) The mean expression per cell of pathways pPPARγ, pSTING, IL31, IFNβ, pRF3, pTBK1, IFNγ, IL4, IL17, and pERK was compared between AS and DM skin lesions. No significant differences between DM and AS were observed for pPPARγ, pSTING, IL31, IFNβ, pTBK1, IFNγ, and pERK. DM skin had increased expression of pIRF3, IL4, and IL17. b-g) DM and AS mDCs express IFNβ. CD11C mDCs (red, b,e) overlap with IFNβ (green, c,f) as seen in yellow (d,g). Individual mDCs overlapping with IFNβ are highlighted with white arrows. Nuclei represented with Ir-Intercalator (blue, b-g). Scale bars (gray) = 50μm h) DM and AS mDCs do not differ in mean IFNβ expression at a single cell level. * p < 0.05, ** p < 0.01,


Disclosure: J. Patel, None; A. Ravishankar, None; S. Maddukuri, None; C. Bax, None; V. Werth, Biogen, 2, 5.

To cite this abstract in AMA style:

Patel J, Ravishankar A, Maddukuri S, Bax C, Werth V. Evaluating the Cellular Composition of Anti-synthetase Syndrome and Dermatomyositis Skin Lesions Using Image Mass Cytometry [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/evaluating-the-cellular-composition-of-anti-synthetase-syndrome-and-dermatomyositis-skin-lesions-using-image-mass-cytometry/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/evaluating-the-cellular-composition-of-anti-synthetase-syndrome-and-dermatomyositis-skin-lesions-using-image-mass-cytometry/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology